bevacizumab + carboplatin + doxorubicin + lapatinib + paclitaxel + trastuzumab

This is a multi-agent combination regimen consisting of six distinct anticancer drugs: - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. - **Carboplatin** is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity. - **Lapatinib** is an oral small molecule tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/HER1) and human epidermal growth factor receptor 2 (HER2/ErbB2). - **Paclitaxel** is a taxane chemotherapeutic that stabilizes microtubules, preventing cell division. - **Trastuzumab** is a monoclonal antibody directed against HER2/ErbB2, blocking downstream signaling in HER2-positive cancers. This combination brings together antiangiogenic therapy, targeted therapies against HER family receptors, and multiple cytotoxic agents. While combinations of several of these agents are used in breast cancer and ovarian cancer regimens—especially for HER2-positive or platinum-sensitive disease—this exact six-drug combination does not correspond to any standard named regimen but represents an intensive investigational or off-label approach for aggressive or refractory cancers[1][5][6].